Bicycle Therapeutics plc

26.25+0.3400+1.31%Vol 276.65K1Y Perf -10.44%
Aug 12th, 2022 16:00 DELAYED
BID21.00 ASK26.62
Open26.41 Previous Close25.91
Pre-Market- After-Market-
 - -  - -%
Target Price
63.50 
Analyst Rating
Strong Buy 1.42
Potential %
141.91 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★★★     56.78
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
28.34 
Earnings Rating
Strong Sell
Market Cap779.00M 
Earnings Date
4th Aug 2022
Alpha0.02 Standard Deviation0.20
Beta0.53 

Today's Price Range

25.300.00

52W Range

12.0862.08

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
0.19%
1 Month
22.78%
3 Months
51.30%
6 Months
-46.15%
1 Year
-10.44%
3 Years
243.14%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BCYC26.250.34001.31
AAPL172.123.63002.15
GOOG122.652.83002.36
MSFT291.914.89001.70
XOM94.000.81000.87
WFC45.940.69001.52
JNJ165.30-1.8400-1.10
FB196.640.99000.51
GE79.931.03001.31
JPM122.131.99001.66
 
ProfitabilityValueIndustryS&P 500US Markets
-
-525.00
-514.10
-464.40
-
RevenueValueIndustryS&P 500US Markets
16.34M
0.55
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.82-0.90-9.76
Q01 2022-0.70-0.93-32.86
Q04 2021-0.60-0.63-5.00
Q03 2021-0.67-0.5911.94
Q02 2021-0.72-0.74-2.78
Q01 2021-0.66-0.73-10.61
Q04 2020-0.50-0.83-66.00
Q03 2020-0.66-0.5221.21
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.82-6.49Negative
9/2022 QR-0.87-7.41Negative
12/2022 FY-3.51-15.08Negative
12/2023 FY-4.04-4.94Negative
Next Report Date-
Estimated EPS Next Report-0.82
Estimates Count8
EPS Growth Next 5 Years %-
Volume Overview
Volume276.65K
Shares Outstanding29.68K
Shares Float29.02M
Trades Count3.48K
Dollar Volume7.20M
Avg. Volume275.43K
Avg. Weekly Volume243.34K
Avg. Monthly Volume223.30K
Avg. Quarterly Volume359.66K

Bicycle Therapeutics plc (NASDAQ: BCYC) stock closed at 26.25 per share at the end of the most recent trading day (a 1.31% change compared to the prior day closing price) with a volume of 276.65K shares and market capitalization of 779.00M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 81 people. Bicycle Therapeutics plc CEO is Kevin Lee.

The one-year performance of Bicycle Therapeutics plc stock is -10.44%, while year-to-date (YTD) performance is -56.88%. BCYC stock has a five-year performance of %. Its 52-week range is between 12.08 and 62.075, which gives BCYC stock a 52-week price range ratio of 28.34%

Bicycle Therapeutics plc currently has a PE ratio of -8.60, a price-to-book (PB) ratio of 2.47, a price-to-sale (PS) ratio of 47.05, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -25.94%, a ROC of -31.95% and a ROE of -38.42%. The company’s profit margin is -%, its EBITDA margin is -514.10%, and its revenue ttm is $16.34 Million , which makes it $0.55 revenue per share.

Of the last four earnings reports from Bicycle Therapeutics plc, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.82 for the next earnings report. Bicycle Therapeutics plc’s next earnings report date is -.

The consensus rating of Wall Street analysts for Bicycle Therapeutics plc is Strong Buy (1.42), with a target price of $63.5, which is +141.91% compared to the current price. The earnings rating for Bicycle Therapeutics plc stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bicycle Therapeutics plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bicycle Therapeutics plc has a Buy technical analysis rating based on Technical Indicators (ADX : 10.87, ATR14 : 1.96, CCI20 : 80.56, Chaikin Money Flow : 0.17, MACD : 2.05, Money Flow Index : 57.46, ROC : 7.80, RSI : 60.60, STOCH (14,3) : 64.19, STOCH RSI : 0.07, UO : 55.35, Williams %R : -35.81), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bicycle Therapeutics plc in the last 12-months were: Alistair Milnes (Option Excercise at a value of $103 719), Dominic Smethurst (Option Excercise at a value of $111 300), Kevin Lee (Option Excercise at a value of $491 652), Kevin Lee (Sold 55 118 shares of value $2 250 189 ), Nicholas Keen (Option Excercise at a value of $216 678), Nicholas Keen (Sold 18 321 shares of value $774 682 ), Pierre Legault (Option Excercise at a value of $1 269 686), Pierre Legault (Sold 150 000 shares of value $8 653 889 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (75.00 %)
8 (72.73 %)
8 (72.73 %)
Moderate Buy
1 (8.33 %)
1 (9.09 %)
1 (9.09 %)
Hold
2 (16.67 %)
2 (18.18 %)
2 (18.18 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.42
Strong Buy
1.45
Strong Buy
1.45

Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need.

CEO: Kevin Lee

Telephone: +44 1223261503

Address: B900, Babraham Research Campus, Cambridge CB22 3AT, , GB

Number of employees: 81

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

33%67%

Bearish Bullish

65%35%

Bearish Bullish

66%34%

TipRanks News for BCYC

Fri, 05 Aug 2022 04:53 GMT Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Bicycle Therapeutics (BCYC) and OrthoPediatrics (KIDS)

- TipRanks. All rights reserved.

Mon, 06 Jun 2022 04:25 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicycle Therapeutics (BCYC), Turning Point Therapeutics (TPTX) and Globus Medical (GMED)

- TipRanks. All rights reserved.

Thu, 03 Mar 2022 10:18 GMT Bicycle Therapeutics (BCYC) Gets a Buy Rating from Leerink Partners

- TipRanks. All rights reserved.

Wed, 02 Mar 2022 11:28 GMT Bicycle Therapeutics (BCYC) Receives a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

Thu, 06 Jan 2022 05:16 GMT Bicycle Therapeutics (BCYC) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Wed, 05 Jan 2022 14:35 GMT Bicycle Therapeutics (BCYC) Gets a Buy Rating from Needham

- TipRanks. All rights reserved.

News

Stocktwits